Enlivex (ENLV) Non Operating Income (2013 - 2025)
Enlivex (ENLV) posted Non Operating Income of $285000.0 for Q4 2025, down 19.03% on a QoQ basis from $352000.0 in Q3 2025, and down 37.5% year-over-year from $456000.0 in Q4 2024.
Analysis
Enlivex (ENLV) Non Operating Income (2013 - 2025) Analysis & Trends
Enlivex has reported Non Operating Income for 11 years, with the latest figure at $285000.0 in Q4 2025.
- On a quarterly basis, Non Operating Income fell 37.5% year-over-year to $285000.0 in Q4 2025; TTM through Dec 2025 was $2.3 million, a 163.5% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 120.59% from the prior year.
- Non Operating Income was $285000.0 for Q4 2025 at Enlivex, down from $352000.0 in the prior quarter.
- The five-year high for Non Operating Income was $1.2 million in Q2 2025, with the low at -$435000.0 in Q1 2023.
- Average Non Operating Income over 3 years is $285750.0, with a median of $318500.0 recorded in 2025.
- The largest YoY upside for Non Operating Income was 1200.0% in 2025 against a maximum downside of 37.5% in 2025.
- Over 3 years, Non Operating Income stood at -$435000.0 in 2023, then surged by 204.83% to $456000.0 in 2024, then plunged by 37.5% to $285000.0 in 2025.
- The last three Non Operating Income figures came in at $285000.0 (Q4 2025), $352000.0 (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Enlivex | 3.17 Mn | -2.59 Mn | - | 285,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 285,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Dec 31, 2024 | 456,000.00 |
| Sep 30, 2024 | 517,000.00 |
| Jun 30, 2024 | -110,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2023 | -435,000.00 |
| Sep 30, 2020 | -166,000.00 |
| Jun 30, 2020 | -808,000.00 |
| Mar 31, 2020 | 1.10 Mn |
| Sep 30, 2019 | -270,000.00 |
| Jun 30, 2019 | -164,000.00 |
| Mar 31, 2019 | -303,000.00 |
| Sep 30, 2018 | 139,000.00 |
| Jun 30, 2018 | 317,000.00 |
| Mar 31, 2018 | -117,000.00 |
| Dec 31, 2017 | 13,000.00 |
| Sep 30, 2017 | -4,000.00 |
| Jun 30, 2017 | 21,000.00 |